3 Australian Founder Led Stocks With Revenue Growth Up To 37%

Rate hikes are back in the spotlight after a Federal Reserve official backed another increase because inflation has stayed stubborn. Higher global borrowing costs ripple into Australian markets and can punish businesses that lack clear leadership and focus. Founder-led Australian companies, where the person who built the business still steers it, can offer a different kind of resilience. This article breaks down three such stocks from this focused group.

The three founder-led stocks below are only a small sample, and the full screen surfaced 82 more businesses with equally compelling backstories that are not covered here. To go beyond the shortlist and start identifying your own high-conviction founder plays, head straight into the Founder-Led Companies screener.

Pro Medicus (ASX:PME)

Overview: Pro Medicus provides founder-led medical imaging software platforms like Visage 7 and Visage RIS/PACS that power radiology workflows in hospitals and imaging centers.

Operations: Pro Medicus generates about A$261.7 million from integrated healthcare imaging software, with key hospital and imaging providers across Australia, North America and Europe.

Market Cap: A$17.3b

For a founder-led screener focused on long-term legacies, Pro Medicus matters because Visage 7 and related platforms still reflect the original builders’ product vision, which now underpins how many high-end radiology departments actually work day to day.

"Radiologists at top US hospitals have started demanding it as a condition of employment; they simply won't join institutions that don't run Visage, the company's flagship imaging platform."

What happens to Pro Medicus if one unseen pressure subtly shifts how hospitals think about paying for that level of reliance?

If that pressure is starting to build, the full narrative for Pro Medicus explains how Pro Medicus could keep hospitals close, even as pricing power, contracts and regulation evolve.

Mesoblast (ASX:MSB)

Overview: Mesoblast develops founder-led mesenchymal stromal cell therapies like remestemcel-L that target severe inflammatory and cardiovascular conditions using regenerative medicine.

Operations: Mesoblast generates about $120 million from developing and commercializing its allogeneic cellular medicines platform built around mesenchymal lineage cell therapies.

Market Cap: A$2.8b

Mesoblast matters for a founder-led screen because the same leadership backing remestemcel-L from early trials to commercialization is still steering key decisions today.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

What really tests that founder-driven blueprint is how one unresolved question around long-term demand and pricing ultimately shapes the earning power of this platform.

That unresolved question sits at the center of the full narrative for Mesoblast, which maps how Mesoblast could convert its platform into accelerating demand while pricing risks stay contained.

Harvey Norman Holdings (ASX:HVN)

Overview: Harvey Norman Holdings is a founder-led retailer and property owner that runs big-box furniture, bedding, electrical and technology stores alongside franchise and leasing operations.

Operations: Harvey Norman generates about A$3 billion in sales, mostly from New Zealand, Ireland, Singapore and Malaysia, with smaller contributions from Slovenia, Croatia, the UK and non-franchised outlets.

Market Cap: A$5.1b

Harvey Norman matters to a founder-led screen because Gerry Harvey’s long involvement, ownership and public leadership keep day-to-day decisions tightly tied to the original playbook that blends retail, franchises and a large property portfolio.

"It is worth noting, however, that just over 20% of 2025 profit can be attributed to property revaluations, non-cash gains that can be volatile and are not recurring operational earnings."

What happens if a single shift in how those underlying earnings hold up against competitors quietly resets the market’s patience with this founder-led model?

That patience reset is exactly what the full narrative for Harvey Norman Holdings unpacks, showing how Harvey Norman Holdings could keep compounding store economics even if property gains stall.

Seeking Fresh Alternatives Before They Fly

Some of the most interesting stories move first and get noticed later. Spot potential breakout momentum and under-the-radar ideas while it matters, then get in early.

• Track income streams that could stay steady even when sentiment swings by scanning a curated pool of 3 dividend fortresses built to keep cash flows front and center.
• Hunt for future infrastructure leaders with a focused look at 40 power grid technology and infrastructure stocks before investment momentum crowds into the same limited set of listed plays.
• Zero in on compounding potential where strong balance sheets meet quality fundamentals through a hand-picked list of solid balance sheet and fundamentals (12 results) before valuations get caught re-rating higher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com